Mefloquine developing world is about US$0.6–1.3 per dose. In the United States it costs about $10 a dose. Mefloquine is used to both prevent and treat certain forms of malaria. Mefloquine is useful for the prevention of malaria in all areas except for those where parasites may have resistance to multiple medications, and is one of several anti-malarial medications recommended by the United States Centers for Disease Control and Prevention for this purpose. It is also recommended by the Infectious Disease Society of America for malaria prophylaxis as a first or second-line agent, depending on resistance patterns in the malaria found
Mefloquine of the users reported severe events requiring medical attention, vs 1.2% in the atovaquone-proguanil arm. The brand name drug, Lariam, is manufactured by the Swiss company Hoffmann–La Roche. In August 2009, Roche stopped marketing Lariam in the United States. In June 2010, the first case report appeared of a progressive multifocal leukoencephalopathy being successfully treated with mefloquine. Mefloquine can also act against the JC virus. Administration of mefloquine seemed to eliminate the virus from the patient's body and prevented further neurological deterioration. WRAIR has published several papers outlining ongoing efforts at that institution to make mefloquine safer by producing a